Sun, Apr 20, 2014, 9:34 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

  • sirmichael222 sirmichael222 May 18, 2013 11:52 PM Flag

    Zertane

    If I understand it correctly, the Zertane situation is nothing to be concerned about. We all thought a Zertane deal was a sure thing. Apparently it wasn't. According to what Ampio has posted as being their presentation this coming Wednesday, they are in an ongoing search to find a partner to complete everything and do some kind of a deal. According to their investor relations person, if no such partner is found, Ampio itself will pay for the trial (expected to cost only about 4 million dollars). It's only a big deal to those of us who were hoping for things to materialize more quickly. The drug either works or it doesn't; that's what's important; and the final trial will decide whether or not the FDA approves it.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • " According to what Ampio has posted as being their presentation this coming Wednesday, they are in an ongoing search to find a partner to complete everything and do some kind of a deal. According to their investor relations person, if no such partner is found, Ampio itself will pay for the trial (expected to cost only about 4 million dollars)."

      How's that working out? It's been almost 6 weeks.....

    • It's a big deal because AMPE doesn't have the cash to finance the trial themselves. They'll need to do a Secondary sooner or later if there is no Zertane deal. The other question that needs to be asked - what happened to the big Pharma partner that they said went to the FDA with them regarding the future Zertane trial last year? All of a sudden it lost interest? Not good.

 
AMPE
5.44-0.08(-1.45%)Apr 17 4:07 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.